Through the acquisition, the companies plan to build a global science-based organization that uses product innovation to enhance ABITEC’s scientific and commercial interests.
ABITEC, an ABF Ingredients company, announced on July 8, 2020 that it has acquired Larodan AB, a Sweden-based manufacturer and international marketer of high-purity research grade lipids, to expand its lipid product offerings and scientific capabilities.
Through the acquisition, the companies plan to build a global science-based organization that uses product innovation to enhance ABITEC’s scientific and commercial interests, an ABITEC press release said. Additionally, the acquisition will introduce ABITEC to the field of Lipidomics which gives researchers the ability to identify the roles of lipids across various health and disease states at the chemical level.
“Larodan is a world leader in the field of analytical-grade lipids, and their scientific capabilities will not only expand ABITEC’s technical expertise but will also provide us with a strategic R&D location in Europe. The Larodan team has done an exceptional job in the development, manufacturing, and global commercialization of their unique and highly specialized lipid reagents, and we are thrilled to have them join the ABITEC team. We share a common passion for innovation and lipids, and I look forward to us working together to grow and expand their brand in the US markets and across the globe,” said Jeff Walton, CEO of ABITEC, in the press release.
“We are very happy to find a new home with ABITEC, with whom we share a deep interest in lipids. Together we can immediately offer a more comprehensive service to our American customers, including larger volumes and GMP grades,” said Fredrik Lindgren, selling shareholder and continuing managing director of Larodan, in the press release.
Source: ABITEC
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.